Park Avenue Securities LLC Has $1.61 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Park Avenue Securities LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,671 shares of the biopharmaceutical company’s stock after purchasing an additional 141 shares during the quarter. Park Avenue Securities LLC’s holdings in Regeneron Pharmaceuticals were worth $1,609,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in REGN. Stifel Financial Corp lifted its stake in shares of Regeneron Pharmaceuticals by 12.2% in the third quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock worth $25,537,000 after acquiring an additional 3,385 shares during the period. Sierra Summit Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $1,011,000. LPL Financial LLC lifted its stake in shares of Regeneron Pharmaceuticals by 9.3% in the third quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock worth $33,522,000 after acquiring an additional 3,479 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $749,000. Finally, Public Employees Retirement Association of Colorado lifted its stake in shares of Regeneron Pharmaceuticals by 16.0% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 16,074 shares of the biopharmaceutical company’s stock worth $14,118,000 after acquiring an additional 2,220 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at $1,347,256.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $1,011.00, for a total value of $836,097.00. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at $1,397,202. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,347,256.52. The disclosure for this sale can be found here. Insiders have sold a total of 61,215 shares of company stock valued at $60,414,782 over the last 90 days. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.8 %

Shares of NASDAQ:REGN opened at $1,053.14 on Monday. The stock has a market cap of $116.05 billion, a price-to-earnings ratio of 31.11, a PEG ratio of 2.16 and a beta of 0.13. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $1,059.80. The business’s 50 day moving average is $967.84 and its 200 day moving average is $944.29.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). The company had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective on the stock. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. Truist Financial reiterated a “buy” rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Cantor Fitzgerald reiterated a “neutral” rating and issued a $925.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, May 3rd. Finally, Royal Bank of Canada lifted their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,229.00 and gave the stock an “outperform” rating in a report on Wednesday, June 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $998.09.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.